Epilepsy Research
Volume 30, Issue 1 , Pages 31-40 , March 1998

A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures

  • Reetta Kälviäinen

      Affiliations

    • Department of Neurology, University Hospital of Kuopio, Kuopio, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 17 173311; fax: +358 17 173031.
    • ,
  • Martin J Brodie

      Affiliations

    • Epilepsy Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK
    • ,
  • John Duncan

      Affiliations

    • Chalfont Centre for Epilepsy, Buckinghamshire, UK
    • ,
  • David Chadwick

      Affiliations

    • Department of Neurological Science, The Walton Centre for Neurology and Neurosurgery, University of Liverpool, Liverpool, UK
    • ,
  • David Edwards

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark
    • ,
  • Karsten Lyby

      Affiliations

    • Novo Nordisk A/S, Bagsvaerd, Denmark
    • ,
  • for the Northern European Tiagabine Study Group

Received 20 September 1997 ,Accepted 10 October 1997.

References 

  1. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 1995;36(Suppl. 6):S14–S21
  2. Braestrup C, Nielsen EB, Sonnewald U, Knutsen LJS, Andersen KE, Jansen JA, et al. NO-328 binds with high affinity to the brain uptake carrier. J. Neurochem. 1990;54:639–647
  3. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia. 1997;38:S23–S27
  4. Commission on Classification and Terminology of the International League Against Epilepsy . Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1991;32(Suppl. 3):15
  5. COSTART, 1989. Coding Symbols for Thesaurus of Adverse Reaction Terms, 3rd ed. Department of Health and Human Services, Food and Drug Administration, Rockville, MD.
  6. Crawford PM, Engelsman M, Brown SW, Rentmeester TW, Pedersen B, Clarke CE, et al. Tiagabine: phase II study of efficacy and safety in adjunctive treatment of partial seizures. Epilepsia. 1993;34(Suppl. 2):182
  7. Gustavson LE, Chu S-Y. High performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J. Chromatogr. 1992;574:313–318
  8. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 1995;36:605–611
  9. Gustavson, L.E., Cato, A., Boellner, S.W., Cao, G.X., Quian, J.X., Guenther, H.J., Sommerville, K.W., 1997. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Online J. Curr. Clin. Trials 6, February 3, Doc No. 202, Internet <www.ojcct.com>.
  10. Gustavson, L.E., Sommerville, K.W., Boellner, S.W., Witt, G.F., Guenther, H.J., Granneman, G.R., 1997. Lack of clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Online J. Curr. Clin. Trials 6, February 18, Doc No. 203, Internet <www.ojcct.com>.
  11. Leppik HE. Tiagabine: the safety landscape. Epilepsia. 1995;36(Suppl. 6):S10–S13
  12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959;22:719–748
  13. Meldrum BS. Anatomy, physiology and pathology of epilepsy. Lancet. 1990;336:231–234
  14. Metha CR, Patel NR, Gray R. On computing an exact confidence interval for the common odds ratio in several 2×2 contingency tables. Biometrics. 1985;40:819–825
  15. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C. Characterisation of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur. J. Pharmacol. 1991;96:257–266
  16. Pledger GW, Schmidt D. Evaluation of antiepileptic drug efficacy: a review of clinical trial design. Drugs. 1994;48:498–509
  17. Richens A, Chadwick DW, Duncan JS, Dam M, Gram L, Mikkelsen M, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. 1995;21:37–42
  18. Sachdeo RC, Leroy R, Krauss G, Drake M, Green PM, Leppik I, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch. Neurol. 1997;54:595–601
  19. So EL, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res. 1995;22:221–226
  20. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 1995;316:612–626
  21. Uthman, B., Rowan, J., Ahmann, P.A., Leppik, I.E., Schachter, S.C., Sommerville, K.W.S., Shu, V., 1998. Multicenter randomized dose-response trial of tiagabine as adjunctive therapy for patients with complex partial seizures. Arch. Neurol. (in press).
  22. van Elteren PH. On the combination of independent two sample tests of Wilcoxon. Bull. Inst. Int. Stat. 1960;37:351–361
  23. Zelen M. The analysis of several 2×2 contingency tables. Biometrika. 1971;58:129–137

PII: S0920-1211(97)00082-X

Epilepsy Research
Volume 30, Issue 1 , Pages 31-40 , March 1998

Article Tools

* Image Usage & Resolution